AU2012332952B2 - Pazopanib formulation - Google Patents

Pazopanib formulation Download PDF

Info

Publication number
AU2012332952B2
AU2012332952B2 AU2012332952A AU2012332952A AU2012332952B2 AU 2012332952 B2 AU2012332952 B2 AU 2012332952B2 AU 2012332952 A AU2012332952 A AU 2012332952A AU 2012332952 A AU2012332952 A AU 2012332952A AU 2012332952 B2 AU2012332952 B2 AU 2012332952B2
Authority
AU
Australia
Prior art keywords
indazol
pyrimidinyl
methylamino
dimethyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012332952A
Other languages
English (en)
Other versions
AU2012332952A1 (en
Inventor
Gossett Augustus Campbell
Helen RICHARDSON
Peter A. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2012332952A1 publication Critical patent/AU2012332952A1/en
Application granted granted Critical
Publication of AU2012332952B2 publication Critical patent/AU2012332952B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012332952A 2011-10-31 2012-10-16 Pazopanib formulation Ceased AU2012332952B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553454P 2011-10-31 2011-10-31
US61/553,454 2011-10-31
PCT/US2012/060361 WO2013066616A1 (en) 2011-10-31 2012-10-16 Pazopanib formulation

Publications (2)

Publication Number Publication Date
AU2012332952A1 AU2012332952A1 (en) 2014-05-15
AU2012332952B2 true AU2012332952B2 (en) 2016-05-05

Family

ID=48192602

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012332952A Ceased AU2012332952B2 (en) 2011-10-31 2012-10-16 Pazopanib formulation

Country Status (12)

Country Link
US (3) US9278099B2 (enExample)
EP (1) EP2773204A4 (enExample)
JP (2) JP6200893B2 (enExample)
KR (1) KR101993436B1 (enExample)
CN (1) CN104254249B (enExample)
AU (1) AU2012332952B2 (enExample)
BR (1) BR112014010551A2 (enExample)
CA (1) CA2852912A1 (enExample)
HK (1) HK1201685A1 (enExample)
IN (1) IN2014CN02850A (enExample)
RU (1) RU2616500C2 (enExample)
WO (1) WO2013066616A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA201502073B (en) * 2014-03-28 2016-03-30 Cipla Ltd Pharmaceutical composition
JP7108018B2 (ja) 2017-04-17 2022-07-27 イエール ユニバーシティ 急性肺傷害を処置または予防する化合物、組成物および方法
WO2019053500A1 (en) 2018-04-17 2019-03-21 Alvogen Malta Operations (Row) Ltd PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME
MX395463B (es) 2018-04-24 2025-03-25 Shionogi & Co Forma de dosificacion solida que tiene excelente estabilidad
KR102501180B1 (ko) 2018-04-24 2023-02-21 시오노기세야쿠 가부시키가이샤 안정성이 우수한 고형 제제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064752A2 (en) * 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
WO2007089445A2 (en) * 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations
US20090005406A1 (en) * 2005-11-29 2009-01-01 Smithkline Beecham Corporation Cancer Treatment Method
US20100267787A1 (en) * 2007-11-12 2010-10-21 Gregory Harasymiw Pharmaceutical Compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675537A5 (enExample) * 1988-03-25 1990-10-15 Ciba Geigy Ag
ES2054089T3 (es) 1988-11-10 1994-08-01 Ciba Geigy Ag Formulaciones orales liquidas.
ES2556946T3 (es) * 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
ES2201932B2 (es) * 2001-11-23 2005-03-16 Glaxo Group Limited Composicion farmaceutica.
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
WO2010037095A2 (en) * 2008-09-29 2010-04-01 Nometics Agents and methods for the treatment of cancer
US20100291025A1 (en) * 2009-04-13 2010-11-18 Auspex Pharmaceuticals, Inc. Indazole inhibitors of tyrosine kinase
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
US8501811B2 (en) * 2010-06-17 2013-08-06 Washington University TASPASE1 inhibitors and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064752A2 (en) * 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
US20090005406A1 (en) * 2005-11-29 2009-01-01 Smithkline Beecham Corporation Cancer Treatment Method
WO2007089445A2 (en) * 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations
US20100267787A1 (en) * 2007-11-12 2010-10-21 Gregory Harasymiw Pharmaceutical Compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEATH, E.L. et al. Investigational New Drugs: The Journal of New Anticancer Agents (2012) Vol.30 No.4 pages 1566 to 1574 *

Also Published As

Publication number Publication date
BR112014010551A2 (pt) 2017-05-02
KR20140096082A (ko) 2014-08-04
JP6423484B2 (ja) 2018-11-14
US10080802B2 (en) 2018-09-25
US10596263B2 (en) 2020-03-24
EP2773204A1 (en) 2014-09-10
WO2013066616A1 (en) 2013-05-10
HK1201685A1 (en) 2015-09-11
US20160120988A1 (en) 2016-05-05
IN2014CN02850A (enExample) 2015-07-03
JP2017197542A (ja) 2017-11-02
CN104254249A (zh) 2014-12-31
US20180360971A1 (en) 2018-12-20
JP2014534215A (ja) 2014-12-18
CA2852912A1 (en) 2013-05-10
RU2014115289A (ru) 2015-12-10
RU2616500C2 (ru) 2017-04-17
US20140255505A1 (en) 2014-09-11
US9278099B2 (en) 2016-03-08
CN104254249B (zh) 2017-02-15
AU2012332952A1 (en) 2014-05-15
KR101993436B1 (ko) 2019-06-26
JP6200893B2 (ja) 2017-09-20
EP2773204A4 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
US10596263B2 (en) Pazopanib formulation
JP5202856B2 (ja) トシル酸トスフロキサシンを含有する粒状固形製剤
US20100022577A1 (en) Dry syrup containing loratadine
JP2026010001A (ja) 経口投与用エダラボン懸濁剤
SG184950A1 (en) Fexofenadine-based composition and preparation process therefor
CN108366956B (zh) 物理和化学稳定的吉维诺司他口服混悬液
CN110545818A (zh) 拉莫三嗪悬浮剂剂型
JP2022031345A (ja) Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤
JP4640821B2 (ja) 難水溶性薬物を含むドライシロップ剤
EP3806821B1 (en) Oral compositions comprising methylprednisolone sodium succinate
CN115837012A (zh) 一种氨氯地平干混悬剂及其制备方法
JP5799061B2 (ja) トスフロキサシンおよびポリビニルピロリドンを含有する粒状固形製剤
JP2004522698A (ja) 医薬組成物のための香料系およびそのような組成物の製造方法
KR101458670B1 (ko) 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법
WO2014007780A1 (en) Orally-disintegrating formulations of dexketoprofen
EA011559B1 (ru) Способ получения быстрорастворимого порошка имидаприла

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CAMPBELL, GOSSETT AUGUSTUS; RICHARDSON, HELEN AND WILLIAMS, PETER A.

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CAMPBELL, GOSSETT AUGUSTUS; RICHARDSON, HELEN AND WILLIAMS, PETER A.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired